Innovation in oncology is facing a significant hurdle when it comes to identifying novel targets, this is the belief of...
DISCO Pharma’s Surfaceome Technology Unlocks Novel Cancer-Selective Targets
Roman Thomas, co-founder and CEO of DISCO Pharmaceuticals, outlines how the company’s surfaceome technology could disrupt drug discovery in oncology.
